GlassScriptPhysician profile
John David Horwhat
NPI 1487747242
$5,335.96
in general payments reported to CMS, 2019-2025
29 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $384 · 2021: $276 · 2022: $553 · 2023: $986 · 2024: $1,062 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,586.61 | 2019-2025 | |
| Boston Scientific Corporation | $617.88 | 2019-2025 | Exalt Model D, Resolution 360 Clip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $612.58 | 2019-2024 | Xifaxan, Plenvu |
| Ardelyx, INC. | $424.58 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $392.58 | 2019-2023 | Entyvio, Gattex |
| Janssen Biotech, INC. | $183.23 | 2022-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $168.82 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $149.24 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $138.96 | 2024-2025 | Voquezna |
| Olympus America INC. | $135.51 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $126.15 | 2025 | Terlivaz |
| Celgene Corporation | $120.47 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $82.14 | 2022-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $76.24 | 2024-2025 | Zenpep |
| Micro-Tech Endoscopy USA, INC. | $66.94 | 2020-2024 | Sureclip |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $63.56 | 2019-2025 | Linzess |
| Pfizer INC. | $57.73 | 2019-2022 | |
| Genzyme Corporation | $51.47 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $45.84 | 2023 | |
| Apollo Endosurgery US INC | $39.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.97 | 2023 | Cyltezo |
| Qol Medical, LLC | $34.20 | 2019 | |
| Intercept Pharmaceuticals, INC. | $31.03 | 2019-2020 | |
| Novo Nordisk INC | $20.17 | 2025 | Wegovy |
| Exact Sciences Corporation | $19.60 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.66 | 2023 | Dificid |
| Shionogi INC | $14.61 | 2019 | |
| Fresenius Kabi USA, LLC | $13.33 | 2024 | Idacio |
| Shire North American Group INC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Horwhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.